首页> 外文OA文献 >A PHASE 2, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EXPLORATORY CLINICAL ACTIVITY OF ALN-TTRSC, AN RNAI THERAPEUTIC FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS

【2h】

A PHASE 2, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EXPLORATORY CLINICAL ACTIVITY OF ALN-TTRSC, AN RNAI THERAPEUTIC FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS

机译：第2阶段，多中心，开放式试验，用于评估ALN-TTRSC（一种用于治疗促甲状腺素介导的心肌淀粉样变的患者的RNA疗法）的安全性，药代动力学，药动学和探索性临床活性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Gillmore Julian David; Falk Rodney; Maurer Mathew; Hanna Mazen; Karsten Verena; Penz Craig; Zimmermann Tracy; Gollob Jared; Hawkins Philip;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis [J] . Julian D Gillmore, Rodney H Falk, Mathew S Maurer, Orphanet journal of rare diseases . 2015,第S1期

机译：Revusiran的2期开放标签扩展（OLE）研究，一种研究性的RNAi治疗药物，用于治疗甲状腺素转甲状腺素蛋白淀粉样变性病
2. First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers [J] . Fox Jonathan C., Hellawell Jennifer L., Rao Satish, Clinical pharmacology in drug development . 2020,第1期

机译：AG10的第一次人类研究，一种用于治疗Transthyretin淀粉样蛋白症状的新型，口服，特异性，选择性和有效的Transthyretin稳定剂：健康成人志愿者的1期安全性，耐受性，药代动力学和药效学研究
3. First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers [J] . Progress in Artificial Intelligence . 2020,第1期

机译：AG10的首先研究，一种用于治疗Transthyretin淀粉样蛋白症的新型，口服，特异性，选择性和有效的Transthyretin稳定剂：健康成人志愿者的第1期安全性，耐受性，药代动力学和药效学研究
4. Statistic Evaluation of the Clinical Benefits of Rehabilitation in Patients with Spine Cord Injury Undergoing Complex Treatment with Specific Therapeutic Factors from Techirghiol Health Resort [C] . Advanced Technologies for Enhanced Quality of Life Meeting . 2009

机译：脊髓损伤患者康复临床益处的统计评价，其特异性治疗特异性治疗因素特异性治疗因素
5. Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial [D] . Saeki Masaomi, 佐伯将臣 2019

机译：充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性：一项多中心，对照，开放标签的临床试验
6. Phase 2 open-label extension (OLE) study of revusiran an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis [O] . Julian D Gillmore, Rodney H Falk, Mathew S Maurer, 2015

机译：Revusiran的2期开放标签扩展（OLE）研究一种研究性RNAi治疗药物用于治疗甲状腺甲状腺激素转甲状腺素样淀粉样变性病
7. Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis [O] . 2015

机译：Revusiran的2期开放标签扩展（OLE）研究，一种研究性RNAi治疗药物，用于治疗甲状腺甲状腺素转基因蛋白淀粉样变性病

A PHASE 2, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EXPLORATORY CLINICAL ACTIVITY OF ALN-TTRSC, AN RNAI THERAPEUTIC FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS

著录项

引文网络

相似文献

相关主题

期刊订阅